In this study we evaluated the QOL in sarcoidosis patients treated with methotrexate employing a general QOL measure, the World Health Organization Quality of Life assessment instrument – WHOQOL- 100.PATIENTS: 72 sarcoidosis patients from the institute of pulmonary diseases, department of sarcoidosis were studied.None of the participating patients had any medical history, which might influence their quality of life patients with comorbidity were excluded. (diabetes, hypertension).The mean time from diagnosis for the whole group of sarcoidosis patients was 3.5 years. The analyzed group was homogeneous according to their demographic characteristics, observing the residence and the life style.Patients were divided into the two groups according to the therapy. Group I patients treated with methotrexate and Group II sarcoidosis patients without any treatment.The hypothesis was that sarcoidosis patients treated with methotrexate due to the serious chronic form of the disease have worse quality of life.All analyses were performed using the Statistical Package for Social Science version10 (SPSS 10).
Analyzing the questions under G 2 (G2.1) and G3 (G2.2) T test for equality of means (Sig. 2 tailed = 0.55) there was no statistical significance between the two groups.The fact that makes the statistically significant difference: T test for equality of means (Sig. 2-tailed = 0.003) between the group treated with methotrexate and not treated sarcoidosis patients is the general question G4 (G2.3) and the general question G1.2.
Although with severe chronic sarcoidosis, treated with methotrexate as a cytotoxic drug, these patients do not have an impression of the worst quality of life than the group of sarcoidosis patients that do not require any treatment at the time of answering the questionnaire.
The treatment with cytotoxic drug, due to the chronic form of the disease, does not influence their general quality of life in the analyzed sarcoidosis patients.
V.V. Vucinic, None.